根治性前列腺切除术后辅助放疗对比早期挽救性放疗联合短期雄激素剥夺治疗:GETUG-AFU 17 随机3期试验
GETUG-AFU 17研究在424例根治性前列腺切除术后切缘阳性、pT3a-pT4a/pNx或pN0的前列腺癌患者中比较辅助放疗与生化复发时挽救性放疗联合6个月曲普瑞林。辅助放疗增加晚期泌尿生殖毒性和勃起功能障碍。
要点
- 辅助放疗与早期挽救性放疗联合短期ADT的5年无事件生存率无显著差异。
- 辅助放疗组晚期≥2级泌尿生殖毒性及勃起功能障碍发生率显著更高。
- 早期挽救性放疗策略可避免部分患者过度放疗及相关不良反应。
核心结论
- 尽管分析缺乏统计效力,辅助放疗对比挽救性放疗未显示无事件生存获益。
- 辅助放疗增加泌尿生殖毒性和勃起功能障碍风险,早期挽救性放疗可减少过度治疗。
研究设计与样本
- 随机、开放标签、多中心3期试验,在46家法国医院开展。
- 纳入424例根治性前列腺切除术后切缘阳性、pT3a/pT3b/pT4a(膀胱颈侵犯)、pNx或pN0的前列腺癌患者,随机1:1分配至辅助放疗或生化复发时挽救性放疗,所有患者接受6个月曲普瑞林。
- 主要终点为无事件生存率,按意向性治疗人群分析;因事件率意外偏低提前终止入组。
主要发现
- 中位随访75个月(IQR 50-100),辅助组74个月,挽救组78个月。
- 挽救组212例中115例(54%)在生化复发后启动治疗,辅助组212例中205例(97%)启动治疗。
- 急性≥3级毒性辅助组6例(3%)、挽救组4例(2%)。
临床怎么用
- 对根治性前列腺切除术后切缘阳性、pT3a-pT4a/pNx或pN0患者,可考虑早期挽救性放疗联合短期雄激素剥夺治疗而非立即辅助放疗。
- 选择辅助放疗时需权衡晚期泌尿生殖毒性和勃起功能障碍风险增加。
局限性
- 研究因事件率低提前终止入组,分析缺乏统计效力。
- 挽救组仅54%患者在生化复发后启动治疗,可能影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance. METHODS: GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069. FINDINGS: Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50-100), 74 months (47-100) in the adjuvant radiotherapy group and 78 months (52-101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86-95) in the adjuvant radiotherapy group and 90% (85-94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001). INTERPRETATION: Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events. FUNDING: French Health Ministry and Ipsen.
引用
- Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020. PMID: 33002438. doi:10.1016/S1470-2045(20)30454-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。